These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 28880867

  • 1. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
    Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y.
    PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
    Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J.
    Blood; 2003 Dec 01; 102(12):3865-70. PubMed ID: 12907443
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
    Saunthararajah Y, DeSimone J.
    Semin Hematol; 2004 Oct 01; 41(4 Suppl 6):11-6. PubMed ID: 15534852
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
    DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, Talischy N.
    Blood; 2002 Jun 01; 99(11):3905-8. PubMed ID: 12010787
    [Abstract] [Full Text] [Related]

  • 10. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
    Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J.
    Blood; 2000 Oct 01; 96(7):2379-84. PubMed ID: 11001887
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
    Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P.
    Int J Cancer; 2012 Jul 01; 131(1):18-29. PubMed ID: 21796622
    [Abstract] [Full Text] [Related]

  • 14. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H, Atweh GF.
    Hematology Am Soc Hematol Educ Program; 2006 Jul 01; ():58-62. PubMed ID: 17124041
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor.
    Gilmartin AG, Groy A, Gore ER, Atkins C, Long ER, Montoute MN, Wu Z, Halsey W, McNulty DE, Ennulat D, Rueda L, Pappalardi M, Kruger RG, McCabe MT, Raoof A, Butlin R, Stowell A, Cockerill M, Waddell I, Ogilvie D, Luengo J, Jordan A, Benowitz AB.
    Haematologica; 2021 Jul 01; 106(7):1979-1987. PubMed ID: 32586904
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP.
    Clin Cancer Res; 2006 Aug 01; 12(15):4619-27. PubMed ID: 16899610
    [Abstract] [Full Text] [Related]

  • 17. 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens.
    Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M.
    Blood; 1985 Sep 01; 66(3):527-32. PubMed ID: 2411310
    [Abstract] [Full Text] [Related]

  • 18. DNA hypo-methylating agents and sickle cell disease.
    Saunthararajah Y, Lavelle D, DeSimone J.
    Br J Haematol; 2004 Sep 01; 126(5):629-36. PubMed ID: 15327513
    [Abstract] [Full Text] [Related]

  • 19. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
    Beumer JH, Eiseman JL, Parise RA, Florian JA, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2008 Aug 01; 62(3):457-64. PubMed ID: 18008070
    [Abstract] [Full Text] [Related]

  • 20. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
    Rivers A, Vaitkus K, Jagadeeswaran R, Ruiz MA, Ibanez V, Ciceri F, Cavalcanti F, Molokie RE, Saunthararajah Y, Engel JD, DeSimone J, Lavelle D.
    Exp Hematol; 2018 Nov 01; 67():60-64.e2. PubMed ID: 30125603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.